Holen Sie sich die Stockscreener-App
3.64
5.45%
-0.21
Handel nachbörslich:
3.63
-0.01
-0.27%
Schlusskurs vom Vortag:
$3.85
Offen:
$3.75
24-Stunden-Volumen:
291.31K
Relative Volume:
0.79
Marktkapitalisierung:
$87.94M
Einnahmen:
$66.58M
Nettoeinkommen (Verlust:
$-19.95M
KGV:
-3.9574
EPS:
-0.9198
Netto-Cashflow:
$-14.27M
1W Leistung:
+23.39%
1M Leistung:
+18.57%
6M Leistung:
-59.60%
1J Leistung:
-36.59%
1-Tages-Spanne:
$3.61
$3.85
1-Wochen-Bereich:
$3.08
$4.13
52-Wochen-Spanne:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Firmenname
Exagen Inc
Sektor
Branche
Telefon
(760) 560-1501
Adresse
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
3.64 | 93.02M | 66.58M | -19.95M | -14.27M | -0.9198 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-11 | Eingeleitet | B. Riley Securities | Buy |
| 2025-07-30 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | Eingeleitet | Craig Hallum | Buy |
| 2022-08-05 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-04-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cowen | Outperform |
| 2019-10-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Exagen Inc Aktie (XGN) Neueste Nachrichten
Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time - MSN
Exagen Inc. (XGN) reports Q1 loss, beats revenue estimates - MSN
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses - MSN
Earnings call transcript: Exagen Inc. beats Q1 2026 expectations, stock surges - Investing.com Nigeria
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Exagen Targets $73 Million Revenue for 2026 as Test Volumes Surge - HarianBasis.co
Exagen Inc. (NASDAQ:XGN) Q1 2026 Earnings Call Transcript - Insider Monkey
TradingKey - TradingKey
Exagen Achieves Record Q1 Revenue Driven by AVISE CTD Adoption - HarianBasis.co
Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Liquidia Technologies (LQDA) - The Globe and Mail
Exagen (XGN) Q1 2026 Earnings Transcript - AOL.com
Exagen Inc stock (US30063K1051): Q1 revenue hits record $17.3M, up 12% - AD HOC NEWS
XGN Maintained by BTIG -- Price Target Lowered to $8.00 - GuruFocus
CCORF Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
BTIG Maintains Exagen(XGN.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Exagen Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Exagen stock price target lowered to $8 by BTIG on valuation - Investing.com UK
Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid Challenges - GuruFocus
Exagen (XGN) Reports Record Q1 Revenue of $17.3 Million, Up 12% Year-Over-Year - GuruFocus
Exagen | 10-Q: Q1 2026 Earnings Report - Moomoo
Number of shareholders of Exagen, Inc. – FWB:E08A - TradingView
Exagen Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-05-12 - Seeking Alpha
TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Is Exagen (XGN) 30.9% Overvalued After Q1 2026 Earnings? EPS -0. - GuruFocus
Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Exagen Q1 earnings call highlights - MSN
XGN Maintains Revenue Forecast for 2026 - GuruFocus
Exagen Inc. Achieves Record $17.3 Million Q1 2026 Revenue - HarianBasis.co
Exagen (XGN) Achieves Strong Q1 Revenue Exceeding Expectations - GuruFocus
Exagen Q1 Earnings Call Highlights - Inkl
Exagen Inc. Reaffirms Earnings Guidance for the full year 2026 - marketscreener.com
Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses - Yahoo Finance
XGN: Record revenue, higher ASP, and strong test volume growth drive positive 2026 outlook - TradingView
Exagen Hits Record Q1 Revenue, Signals Path to Profitability - BriefGlance
Exagen Releases Q1 2026 Financial Results - AlphaStreet
XGN: Q1 2026 revenue up 12% to $17.3M, with margin and ASP gains; guidance reaffirmed - TradingView
Exagen Inc. Reports Record Q1 2026 Revenue and AVISE CTD Average Selling Price - Minichart
Exagen Inc. (NASDAQ:XGN) Soars on Q1 2026 Earnings Beat as Record Revenue and Narrowed Loss Fuel Pre-Market Rally - ChartMill
EXAGEN INC. 1Q 2026: Revenue $17.31M, EPS $(0.17) — 10-Q Summary - TradingView
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Exagen (NASDAQ: XGN) grows Q1 2026 revenue to $17.3M but remains loss-making - Stock Titan
Autoimmune test maker Exagen lifts prices, posts record $17.3M quarter - Stock Titan
Exagen reports Q1 2026 revenue $17.3M, adjusted EBITDA loss narrows to $2.16M - TradingView
XGN: Q1 2026 delivered record revenue, improved margins, and reaffirmed strong full-year guidance - TradingView
Exagen (XGN) posts record Q1 2026 revenue and higher AVISE CTD pricing - Stock Titan
Exagen Inc. Reports First Quarter 2026 Results - Caledonian Record
BRIEF-Exagen Inc. Q1 Revenue USD 17.306 Million Vs. IBES Estimate USD 16.4 Million - TradingView
Finanzdaten der Exagen Inc-Aktie (XGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):